Compare DSGX & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSGX | PTCT |
|---|---|---|
| Founded | 1981 | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 5.7B |
| IPO Year | 1999 | 2006 |
| Metric | DSGX | PTCT |
|---|---|---|
| Price | $71.26 | $69.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 17 |
| Target Price | ★ $105.22 | $80.65 |
| AVG Volume (30 Days) | 554.2K | ★ 733.3K |
| Earning Date | 06-03-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 264.48 |
| EPS | N/A | ★ 7.78 |
| Revenue | N/A | ★ $264,734,000.00 |
| Revenue This Year | $12.05 | N/A |
| Revenue Next Year | N/A | $17.70 |
| P/E Ratio | $37.05 | ★ $8.75 |
| Revenue Growth | N/A | ★ 36.19 |
| 52 Week Low | $62.56 | $35.95 |
| 52 Week High | $117.35 | $87.50 |
| Indicator | DSGX | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 49.29 | 48.31 |
| Support Level | $68.82 | $64.00 |
| Resistance Level | $74.91 | $69.23 |
| Average True Range (ATR) | 2.79 | 2.38 |
| MACD | 0.15 | -0.33 |
| Stochastic Oscillator | 54.92 | 25.12 |
Descartes Systems Group provides a software solution that allows users in the shipping industry to communicate with one another. Its core product is the Global Logistics Network, which is best understood as transaction-driven. Descartes charges clients to send/receive messages, data, and documents on the GLN. Customers typically contract for a monthly minimum over a multiyear period. The GLN platform allows Descartes to upsell additional software modules as well, typically provided via a software-as-a-service model.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.